Fig. 3

circBIRC6 transmitted by EVs enhanced oxaliplatin resistance in pancreatic cancer cells. (A-B) qRT-PCR analysis demonstrating levels of EV-packaged circBIRC6 in CAFs overexpressing (A) or depleted of (B) circBIRC6. (C-H) Panc-1 and MiaPaCa-2 cells exposed to CAF-derived EVs for a week, post which experimental analyses were conducted. (C-D) IC50 value of oxaliplatin-treated pancreatic cancer cells assessed using CCK-8. (E-F) Imaging and quantification of colonies formed by the treated pancreatic cancer cells. (G-H) Imaging and quantification of apoptosis in treated pancreatic cancer cells through flow cytometry. (I-J) Representative organoids derived from pancreatic cancer patients under the specified treatments. Data are expressed as mean ± SD. **p < 0.01, ***p < 0.001